AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16008972
Drug: BiPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP therapy
Trial: 12221159
Drug: Amantadine (usually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (usually 400 mg/d)
Trial: 8554732
Drug: Acute losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute losartan therapy (50 mg single dose)
Trial: 8554732
Drug: Chronic losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic losartan therapy (42 days)
Trial: 122333
Drug: Cimetidine 1g
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1g daily for 4 weeks
Trial: 122333
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets of identical appearance for 4 weeks
Trial: 31127837
Drug: Group acupuncture
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group acupuncture (once weekly for 12 weeks)
Trial: 31127837
Drug: Group acupuncture
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group acupuncture (twice weekly for 12 weeks)
Trial: 31127837
Drug: Group acupuncture
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group acupuncture (once or twice weekly for 12 weeks)
Trial: 28103704
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation counseling and nicotine patches
Trial: 25482435
Drug: Home administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of 200mg mifepristone
Trial: 25482435
Drug: Clinic administration
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic administration of 200mg mifepristone
Trial: 8203982
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH (0.1 mg/kg)
Trial: 8203982
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH (0.2 mg/kg)
Trial: 3316514
Drug: Cyclophosphamide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide monotherapy
Trial: 12612277
Drug: Aqueous nasal
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous nasal beclomethasone (400 micro g/d for 4 weeks, then 200 micro g/d for 24 weeks)
Trial: 12612277
Drug: Aqueous nasal
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous nasal beclomethasone (200 micro g/d for 24 weeks)
Trial: 8627081
Drug: Antibody levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody levels to pertussis toxin (PT) measured by ELISA
Trial: 8627081
Drug: Antibody levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody levels to filamentous hemagglutinin (FHA) measured by ELISA
Trial: 8627081
Drug: Antibody levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody levels to PT and FHA
Trial: 1750720
Drug: Uniphyl tablets
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablets taken with food
Trial: 1750720
Drug: Uniphyl tablets
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablets taken under fasting conditions
Trial: 7149102
Drug: Oxamniquine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (20 mg/kg a day for 3 days)
Trial: 7149102
Drug: Niridazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niridazole (15 mg/kg a day for 8 days)
Trial: 26012289
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (parents record daily symptom scores and receive short messages from doctors)
Trial: 26012289
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (parents do not record daily symptom scores and do not receive short messages)
Trial: 17418836
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of acarbose
Trial: 15119636
Drug: Dialysate volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate volume of 2.0 L
Trial: 15119636
Drug: Dialysate volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate volume of 2.5 L
Trial: 15119636
Drug: Dialysate volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate volume of 3.0 L
Trial: 11515707
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg daily (increased to 10 mg if BP > 140/90 mmHg)
Trial: 11515707
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 20 mg twice daily (increased to 40 mg if BP > 140/90 mmHg)
Trial: 8632551
Drug: Vacuum therapy
RxNorm normalized name: Rapport Vacuum Therapy Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum therapy
Trial: 2842677
Drug: Monovalent Japanese
RxNorm normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent Japanese encephalitis vaccine (n = 21,628)
Trial: 2842677
Drug: Bivalent Japanese
RxNorm normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent Japanese encephalitis vaccine (n = 22,080)
Trial: 2842677
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine groups combined
Trial: 18817474
Drug: LLLT (655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLLT (655 nm) of 5 J at an energy density of 500 J/cm2 administered at four points along the biceps muscle belly
Trial: 18817474
Drug: Placebo LLLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LLLT administered in the same manner
Trial: 16580286
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate (MgSO4) followed by oral nifidepine tocolysis (n = 24)
Trial: 10808210
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B colloidal dispersion (ABCD) 2 mg/kg/day intravenously
Trial: 10808210
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg/day orally
Trial: 8827784
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) therapy for 1 week
Trial: 8827784
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) therapy for 1 week (after discontinuation)
Trial: 1306636
Drug: Beclomethasone Dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate per nasal spray (400 mcg a day)
Trial: 1306636
Drug: Antihistaminical drugs
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistaminical drugs or ketotifen per os and Disodium chromoglycate per nasal spray
Trial: 12351279
Drug: Oral desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral desipramine
Trial: 28341415
Drug: Diuretic strategy
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic strategy based on CA125: high dose if CA125 > 35 U/mL, low doses otherwise
Trial: 28341415
Drug: Standard diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diuretic strategy: titration based on conventional clinical and biochemical evaluation
Trial: 28341415
Drug: Diuretic strategy
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic strategy based on CA125
Trial: 25981372
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 4 kcal/min (ID4)
Trial: 25981372
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 2 kcal/min (ID2)
Trial: 23063790
Drug: Phonophoresis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis of piroxicam (PhP) with 4 grams of 0.5% piroxicam gel, 20mg of piroxicam drug, ultrasound program, continuous mode, 1.0W/cm(2), 10 minutes per session, 5 times per week for 2 weeks.
Trial: 23063790
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (UT) using nondrug coupling gel, ultrasound program, continuous mode, 1.0W/cm(2), 10 minutes per session, 5 times per week for 2 weeks.
Trial: 21750201
Drug: Cixutumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (6 mg/kg IV) and Temsirolimus (25 mg IV)
Trial: 14708410
Drug: H2RA-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin, 0.4 g metronidazole) for 1 week
Trial: 14708410
Drug: H2RA-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin, 0.4 g metronidazole) for 2 weeks
Trial: 14708410
Drug: PPI-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin, 0.4 g metronidazole) for 1 week
Trial: 14708410
Drug: PPI-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin, 0.4 g metronidazole) for 2 weeks
Trial: 10829335
Drug: 12-Step, Minnesota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Step, Minnesota Model treatment (completed treatment)
Trial: 10829335
Drug: 12-Step, Minnesota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Step, Minnesota Model treatment (incomplete treatment)
Trial: 9305460
Drug: lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam 2 mg
Trial: 8321672
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of essential oils of lavender species 1
Trial: 8321672
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of essential oils of lavender species 2
Trial: 2425156
Drug: Pindolol (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (0.02 mg/kg i.v.)
Trial: 2425156
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and Pindolol (both drugs during exercise)
Trial: 29996883
Drug: Repeated non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated non-surgical periodontal therapy
Trial: 29996883
Drug: Standard-of-care and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care and Repeated non-surgical periodontal therapy
Trial: 10485385
Drug: Sublingual-swallow immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets)
Trial: 2201256
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of amphotericin B (group A)
Trial: 2201256
Drug: 4-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour infusion of amphotericin B (group B)
Trial: 6109538
Drug: Betaxolol 10
RxNorm normalized name: betaxolol 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 10 mg daily for 7 days
Trial: 6109538
Drug: Betaxolol 20
RxNorm normalized name: betaxolol 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 20 mg daily for 7 days
Trial: 6109538
Drug: Betaxolol increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol increasing doses up to 60 mg/day for 15 days
Trial: 31574792
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy (GCBT) for 8 consecutive weeks, 2.5-hour sessions each week
Trial: 19181592
Drug: Rocuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.06 mg/kg as a priming dose
Trial: 19181592
Drug: Cisatracurium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.01 mg/kg as a priming dose
Trial: 14725687
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg/orally, twice daily)
Trial: 14725687
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg/orally, twice daily)
Trial: 14725687
Drug: Combined metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metformin (850 mg/orally, twice daily) + flutamide (250 mg/orally, twice daily)
Trial: 10506726
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment group
Trial: 31990246
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin C, thiamine and hydrocortisone
Trial: 31990246
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (control group)
Trial: 28193240
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg/day) for 4 weeks instead of ethambutol
Trial: 28193240
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg/day) for 2 weeks instead of ethambutol
Trial: 28193240
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol)
Trial: 28193240
Drug: Treatment success
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment success rate
Trial: 17202116
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone replacement
Trial: 16086931
Drug: Cholesterol-lowering medications
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering medications
Trial: 11981766
Drug: Transarterial Lipiodol
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial Lipiodol chemoembolization (variable dose of cisplatin in Lipiodol and gelatin-sponge particles, median 4.5 courses per patient)
Trial: 9818107
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine (8 mg)
Trial: 9818107
Drug: 1% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hyperbaric bupivacaine (8 mg)
Trial: 7543348
Drug: Tenidap 120
RxNorm normalized name: tenidap
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap 120 mg/day (once daily)
Trial: 7543348
Drug: Diclofenac 150
RxNorm normalized name: diclofenac sodium 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 150 mg/day (50 mg t.i.d)
Trial: 30926298
Drug: Cervarix® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix® vaccine
Trial: 30926298
Drug: Gardasil® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil® vaccine
Trial: 30926298
Drug: Non-vaccine types
RxNorm normalized name: Adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-vaccine types
Trial: 25302637
Drug: Pea hull
RxNorm normalized name: Pea
DrugBank: Pea (DB10551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea hull fibre (7 g)
Trial: 25302637
Drug: Pea protein
RxNorm normalized name: Pea Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea protein (10 g)
Trial: 25302637
Drug: Pea protein
RxNorm normalized name: Pea Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea protein (10 g) plus hull fibre (7 g)
Trial: 25302637
Drug: Yellow peas
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow peas (406 g)
Trial: 19780738
Drug: Doxycycline capsules
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline capsules 100 mg twice daily plus triple sulfa vaginal cream once daily for ten days
Trial: 19780738
Drug: Doxycycline capsules
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline capsules 100 mg twice daily and triple sulfa vaginal cream once daily plus vitamin C tablets 250 mg once daily for ten days
Trial: 17206698
Drug: Group-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based intervention program consisting of nine weekly sessions, alternating lectures and group therapy sessions.
Trial: 15315180
Drug: Propofol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (6 mg/kg/h)
Trial: 8285592
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy in asymptomatic patients (Mayo asymptomatic trial, Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin trial, VA Asymptomatic Trial)
Trial: 29473908
Drug: l-carnitine-l-tartrate 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine-l-tartrate 1500 mg per day
Trial: 27328737
Drug: Dexamethasone 0.15
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.15 mg·kg(‐1) IV plus sham acupuncture
Trial: 27328737
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at P6 bilaterally and CV13 plus 2 ml of normal saline IV
Trial: 14513588
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of immunoglobulin yolk antibodies (IgY) spray (n = 9)
Trial: 14513588
Drug: 0.15% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% chlorhexidine (CH) spray (positive control group, n = 9)
Trial: 14513588
Drug: Placebo phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo phosphate buffered saline (PBS) spray (negative control group, n = 6)
Trial: 10526263
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with cisplatin (200 mg) and epirubicin (120 mg) via the external carotid artery
Trial: 10526263
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (46 grays)
Trial: 8722937
Drug: Oral teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral teicoplanin
Trial: 8722937
Drug: Oral fusidic
RxNorm normalized name: fusidate
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fusidic acid
Trial: 29873727
Drug: Zilpaterol hydrochloride
RxNorm normalized name: zilpaterol hydrochloride
DrugBank: Zilpaterol (DB11479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilpaterol hydrochloride (ZH) supplementation (90 mg.d‐1 per steer for 20 d)
Trial: 21918977
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum CA-125 levels above 30 U/ml
Trial: 20113825
Drug: Trastuzumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (1 year of treatment, given as neoadjuvant and adjuvant treatment)
Trial: 15471363
Drug: Ibudilast (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (60 mg/day p.o. for four weeks)
Trial: 11531934
Drug: 1alpha‐hydroxyvitamin D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1alpha‐hydroxyvitamin D3 + sequential combined HRT + calcium supplement
Trial: 11531934
Drug: sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential combined HRT + calcium supplement
Trial: 3071594
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care (standardized intensive drug treatment)
Trial: 24886626
Drug: Extra-virgin olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-virgin olive oil consumption increase by 10 g/d